Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies

Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Snyder, Heather S., Sakaan, Sami A., March, Katherine L., Siddique, Osama, Cholankeril, Rosann, Cummings, Carolyn D., Gadiparthi, Chiran, Satapathy, Sanjaya K., Ahmed, Aijaz, Cholankeril, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018310/
https://www.ncbi.nlm.nih.gov/pubmed/29951362
http://dx.doi.org/10.14218/JCTH.2017.00050
Descripción
Sumario:Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-diabetics. Lifestyle modifications, including weight loss, remain the mainstay of treatment for NAFLD, as there are no medications currently indicated for this disease state. Anti-diabetic pharmacologic therapies aimed at improving insulin sensitivity and decreasing insulin production have been studied to determine their potential role in slowing the progression of NAFLD. In this review, we focus on the evidence surrounding anti-diabetic medications and their ability to improve disease progression in patients with NAFLD.

Ejemplares similares